AstraZeneca: Covid vaccine shows positive results in studies
(CercleFinance.com) - Late-stage clinical studies of AstraZeneca's experimental vaccine against Covid-19 have showed a high percentage of patients responding to the product, the drugmaker said on Monday.
Interim analysis of data from 131 patients has showed that the vaccine was highly effective in preventing Covid, with no hospitalisations or severe cases of the disease having been reported in participants, the company said.
A single dose regimen showed 90% efficacy when the vaccine was given as a half dose, followed by a full dose at least one month later, and another dosing regimen showed 62% efficacy when given as two full doses at least one month apart, the biopharmaceutical group said.
The combined analysis from both dosing regimens resulted in an average efficacy of 70%, it pointed out.
An independent data monitoring board determined that the Phase II/III trials met their primary endpoint, meaning that AstraZeneca will now immediately prepare regulatory submission for conditional or early approval of the product.
The company said it is making rapid progress in manufacturing, with a capacity of up to 3 billion doses of the vaccine in 2021, pending regulatory approval.
More data will continue to accumulate and additional analysis will be conducted, the company said, as the trial currently includes over 23,000 participants in the UK and Brazil.
Clinical trials are also being conducted in the US, Japan, Russia, South Africa, Kenya and Latin America with planned trials in other European and Asian countries, enrolling up to 60,000 participants.
For the record, the AZD1222 vaccine was jointly invented by the University of Oxford and its spin-off company, Vaccitech.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Interim analysis of data from 131 patients has showed that the vaccine was highly effective in preventing Covid, with no hospitalisations or severe cases of the disease having been reported in participants, the company said.
A single dose regimen showed 90% efficacy when the vaccine was given as a half dose, followed by a full dose at least one month later, and another dosing regimen showed 62% efficacy when given as two full doses at least one month apart, the biopharmaceutical group said.
The combined analysis from both dosing regimens resulted in an average efficacy of 70%, it pointed out.
An independent data monitoring board determined that the Phase II/III trials met their primary endpoint, meaning that AstraZeneca will now immediately prepare regulatory submission for conditional or early approval of the product.
The company said it is making rapid progress in manufacturing, with a capacity of up to 3 billion doses of the vaccine in 2021, pending regulatory approval.
More data will continue to accumulate and additional analysis will be conducted, the company said, as the trial currently includes over 23,000 participants in the UK and Brazil.
Clinical trials are also being conducted in the US, Japan, Russia, South Africa, Kenya and Latin America with planned trials in other European and Asian countries, enrolling up to 60,000 participants.
For the record, the AZD1222 vaccine was jointly invented by the University of Oxford and its spin-off company, Vaccitech.
Copyright (c) 2020 CercleFinance.com. All rights reserved.